Protective effect of adenosine triphosphate and benidipine separately or together against cardiotoxicity caused by bevacizumab
- 9 December 2022
- journal article
- research article
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 98 (3) , 193-200
Abstract
Bevacizumab is a recombinant humanized monoclonal antibody whose adverse effects include cardiotoxicity. We investigated whether using adenosine triphosphate (ATP) or benidipine either separately or together protects against cardiac damage induced by bevacizumab in rats. Forty Wistar albino male rats were allocated to five groups of eight: bevacizumab (Bv), ATP + bevacizumab (ABv), benidipine + bevacizumab (BBv), ATP + benidipine + bevacizumab (ABBv) and untreated controls. Rats in the ABv group were injected intraperitoneally (i.p.) with 2 mg/kg ATP. The BBv group was given 4 mg/kg benidipine by oral gavage. The ABBv group was injected i.p. with 2 mg/kg ATP and simultaneously administered 4 mg/kg benidipine orally. One hour after administration of ATP, benidipine or normal saline, the Bv, ABv, BBv and ABBv groups were injected i.p. with 10 mg/kg bevacizumab. Malondialdehyde (MDA) and total glutathione (tGSH) levels were measured in cardiac tissue, and troponin I (TP I) and creatine kinase MB (CK-MB) levels were measured in blood samples. Tissue samples were examined for histopathology. We found the lowest TP I, CK-MB and MDA levels and the highest tGSH level in the ABBv group; these results were similar to the control group. Nuclei of cardiomyocytes in the BV group were misshapen and shrunken, and myofibers were disrupted; we also observed eosinophilic degeneration and interstitial edema. Blood capillaries were dilated and congested. We observed amelioration of these findings in the ABBv group. We found that ATP and benidipine alone or in combination reduced cardiac damage associated with the use of bevacizumab. ATP + benidipine combined therapy produced the most favorable results.Keywords
This publication has 21 references indexed in Scilit:
- Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in miceHypertension Research, 2011
- P2 receptor-mediated signaling in mast cell biologyPurinergic Signalling, 2009
- Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in ratEuropean Journal of Pharmacology, 2008
- Molecular basis for sunitinib efficacy and future clinical developmentNature Reviews Drug Discovery, 2007
- Enhancing skin wound healing by direct delivery of intracellular adenosine triphosphateThe American Journal of Surgery, 2007
- Anticancer Agents and CardiotoxicitySeminars in Oncology, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Calcium ions and oxidative cell injuryAnnals of Neurology, 1992
- Oxygen-Derived Free Radicals in Postischemic Tissue InjuryNew England Journal of Medicine, 1985